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1. Introduction 
Currently, controlled ovarian hyperstimulation protocols commonly provide embryos in 
excess of those needed for fresh transfer. Therefore, techniques have been developed to store 
these surplus embryos in liquid nitrogen (referred to as cryopreservation) for an indefinite 
period of time without significant compromise of their quality. Based on data from the 
Centers for Disease Control and Prevention (CDC) from 2001 to 2004, about 18% of all IVF 
cycles in the USA used frozen embryos for transfer. In addition, data from the same registry 
compared live births per transfer using frozen and fresh embryos (25% versus 34% 
respectively) clearly showing that cryopreservation is an important adjunct to maximize the 
efficiency of every single patient’s oocyte retrieval. The fundamental objectives for 
successful cryostorage of cells in liquid nitrogen at -196°C can be summarized as follows: 1) 
arresting the metabolism reversibly, 2) maintaining structural and genetic integrity,  3) 
achieving acceptable survival rates after thawing,  4) maintain of developmental competence 
post thaw and, 5) the technique has to be reliable and repeatable. 
Furthermore, all methods and protocols for cryopreservation should be developed such that 
ice crystals formation and growth inside the cells or tissues must either be eliminated or 
massively suppressed. One recent hotly debated topic in the area of reproductive 
cryobiology is whether slow-cooling or rapid-cooling protocols both satisfy the fundamental 
cryo-biological principles for reduction of damage by ice crystal formation during cooling 
and warming, and which approach is better. It is the case nonetheless, that both methods of 
cryopreservation of biological material include six principal steps: 1) initial exposure to the 
cryoprotectant (intracellular water has to be removed by gradual dehydration, 2) cooling 
(slow/rapid) to subzero temperatures (-196°C), 3) storage at low temperature, 4) 
thawing/warming by gradual rehydration, 5) dilution and removal of the cryoprotectant 
agents and replacement of the cellular and intracellular fluid at precise rate and, 6) recovery 
and return to a physiological environment. 
Although initially reported in 1985 as a successful cryopreservation approach for mouse 
embryos, vitrification has taken a backseat in human assisted reproduction. However, the 
practical advantages of this cryopreservation method have more recently caught the 
attention of many ART laboratories as a feasible alternative to traditional slow freezing 
methods. Since 1985 more than 2,100 publications can be found referring to the topic of 
“vitrification”, which is further evidence of the burgeoning growth of interest in this 
cryopreservation technology. One “drawback” considered by embryologists who are not 
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familiar with the vitrification technique, is the use of higher concentration of 
cryoprotectants, which does potentially mean that the vitrification solutions are more toxic 
than their counterpart solutions used for conventional slow freezing. However, with better 
understanding of the physical and biological principles of vitrification this has lead to 
numerous successful clinical applications of this technique within the field of assisted 
reproduction. As of today, all developmental stages of human embryos cultured in vitro 
have been successfully vitrified and warmed, with resulting offspring. Today, slow freezing 
technology still has the longest clinical track record, and greater ‘comfort level’ amongst 
embryologists. Nevertheless, vitrification with its increasing clinical application is showing 
a trend of greater consistency and better outcomes when compared to slow freezing 
technology. Therefore, when (not if) IVF programs overcome the fear of the ‘unknown’, and 
take on the challenge of the short learning curve with vitrification, then at that point 
vitrification will become the clinical standard for human embryo cryopreservation. 
Cryopreservation at low temperature slows or totally prevents unwanted physical and 
chemical change. The major disadvantage to using low temperature cryostorage is that it 
can lead to the crystallization of water, and thereby this approach can create new and 
unwanted physical and chemical events that may injure the cells that are being preserved. 
Although the results achieved by slow freezing in many cases seem quite successful 
(Gardner et al., 2003; Van den Abbeel et al., 2005), ice crystal formation still renders 
traditional slow-freezing programs generally less consistent in their clinical outcomes. 
Another downside to the slow freezing approach is the time to complete such freezing 
procedures for human embryos, which can range from 1.5 to 5hrs. This is due to the fact that 
the slow rate of cooling attempts to maintain a very delicate balance between multiple 
factors that may result in cellular damage by ice crystallization and osmotic toxicity. 
Traditionally slow-freeze embryo cryopreservation has been a positive contributor to 
cumulative patient pregnancy rates, but ultimately the limitations of current slow-rate 
freezing methods in ART have become more evident in the shootout with vitrification-based 
cryostorage. 
Vitrification is one of the more exciting developments in ART in recent years that attempts 
to avoid ice formation altogether during the cooling process by establishing a glassy or 
vitreous state rather than an ice crystalline state, wherein molecular translational motions 
are arrested without structural reorganisation of the liquid in which the reproductive cells 
are suspended. To achieve this glass-like solidification of living cells for cryostorage, high 
cooling rates in combination with high concentrations of cryoprotectants are used. A 
primary strategy for vitrifying cells and tissue is to increase the speed of thermal 
conductivity, while decreasing the concentration of the vitrificants to reduce their potential 
toxicity. There are two main ways to achieve the vitrification of water inside cells efficiently: 
a) to increase the cooling rate by using special carriers that allow very small volume sizes 
containing the cells to be very rapidly cooled; and b) to find materials with rapid heat 
transfer. However, one has to take into account that every cell seems to require its own 
optimal cooling rate, e.g., mature unfertilized oocytes are much more sensitive to chilling 
injury than any of the cell stages of the pre-implantation embryo.The earliest attempts using 
vitrification as an ice-free cryopreservation method for embryos were first reported in 1985 
(Rall & Fahy, 1985). In 1993 successful vitrification of mouse embryos was demonstrated 
(Ali & Shelton, 1993). Furthermore, bovine oocytes and cleavage-stages were vitrified and 
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warmed successfully a few years later (Vajta et al. 1998). In 1999 and 2000 successful 
pregnancies and deliveries after vitrification and warming of human oocytes were reported 
(Kuleshova et al., 1999; Yoon et al., 2000). Since that time, and because it seems to be that 
both entities appear to be especially chill-sensitive cells in ART, oocytes and blastocysts 
seem to receive a potentially significant boost in survival rates by avoiding ice-
crystallization using vitrification (Walker et al., 2004). In general, vitrification solutions are 
aqueous cryoprotectant solutions that do not freeze when cooled at high cooling rates to 
very low temperature. Interest in vitrification has clearly risen as evinced by the almost 
exponential growth of scientific publications about vitrification. Vitrification is very simple, 
requires no expensive programmable freezing equipment, and relies especially on the 
placement of the embryo in a very small volume of vitrification medium (refered also as 
“minimal volume approach”) that must be cooled at extreme rates not obtainable in 
traditional enclosed cryo-storage devices such as straws and vials. The importance of the use 
of a small volume, also referred to „minimal volume approach“ was described and 
published in 2005 (Kuwayama et al., 2005; Kuwayama, 2007). In general, the rate of 
cooling/warming and the concentration of the cryoprotectant required to achieve 
vitrification are in inversely related. In addition, recent publications have shown the 
dominance of warming rate over cooling rates in the survival of oocytes subjected to a 
vitrification procedure (Serki & Mazur, 2009; Mazur & Seki, 2011). 
During vitrification, by using a cooling rate in the range of 2,500 to 30,000ºC/min or greater, 
water is transformed directly from the liquid phase to a glassy vitrified state. The physical 
definition of vitrification is the solidification of a solution at low temperature, not by ice-
crystallization but by extreme elevation in viscosity during cooling (Fahy et al., 1984; Fahy 
1986). Vitrification of the aqueous solution inside cells can be achieved by increasing the 
speed of temperature change, and by increasing the concentration of the cryoprotectant 
used. However, a major potential drawback of vitrification is the use of high concentration 
of cryoprotectant, and an unintentional negative impact of these cryoprotectants in turn can 
be their toxicity, which may affect the embryo and subsequent development in utero. It is 
therefore essential to achieve a fine balance between the speed of cooling and the 
concentration of the vitrifying cryoprotectants. This is necessitated by the practical limit for 
the rate of cooling, and the biological limit of tolerance of the cells for the concentration of 
toxic cryoprotectants being used to achieve the cryopreserved state. It is important to note 
that recently published papers (Takahashi et al., 2005; Liebermann & Tucker, 2006; 
Liebermann, 2009, 2011) have shown that the use of relatively high concentration of 
cryoprotectants such as 15% (vol/vol) ethylene glycol (EG) used in an equimolar mixture 
with dimethyl sulphoxide (DMSO) had no negative effect on the perinatal outcomes from 
blastocyst transfers following vitrification when compared with those from fresh blastocyst 
transfers. 
Vitrification in principle is a simple technology, that is potentially faster to apply, and 
relatively inexpensive; furthermore, it is becoming clinically established, and is seemingly 
more reliable and consistent than conventional cryopreservation when carried out 
appropriately (Tucker et al., 2003; Liebermann & Tucker, 2004). 
Cryoprotectant agents are essential for the cryopreservation of cells. Basically two groups of 
cryoprotectants exist: 1) permeating (glycerol, ethylene glycol, dimethyl sulphoxide); and 2) non-
permeating (saccharides, protein, polymers) agents. The essential component of a vitrification 
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solution is the permeating agent. These compounds are hydrophilic non-electrolytes with a 
strong dehydrating effect. Furthermore, these CPAs are able to depress the “freezing point” 
of the solution. Regarding the high concentration of cryoprotectant used for vitrification, 
and in view of the known biological and physiochemical effects of cryoprotectants, it is 
suggested that the toxicity of these agents is a key limiting factor in cryobiology. Not only 
does this toxicity prevent the use of fully protective levels of these additives, but it may also 
be manifested in the form of cryo-injury above and beyond that seen occurring due to 
classical causes of cell damage (osmotic toxicity and ice formation) during cryopreservation. 
In spite of this, the permeating CPA should be chosen firstly by their permeating property, 
and secondly on the basis of their potential toxicity. Because the permeating CPA is 
responsible for the toxicity (the key limiting factor in cryobiology), different cryoprotectants 
have been tested for their relative toxicity, and the results indicate that ethylene glycol (EG; 
MW 62.02) is the least toxic followed by glycerol. Additionally, these highly permeating 
cryoprotectants are also more likely to diffuse out of the cells rapidly and the cells regained 
their original volume more quickly upon warming, thus preventing osmotic injury. 
Therefore, the most common and accepted cryoprotectant for vitrification procedures is 
ethylene glycol (EG). Today EG is more commonly used in an equimolar mixture with 
DMSO. Often additives are added to the vitrification solution such as disaccharides. 
Disaccharides, for example sucrose, do not penetrate the cell membrane, but they help to 
draw out more water from cells by osmosis, and therefore lessen the exposure time of the 
cells to the toxic effects of the cryoprotectants. The non-permeating sucrose also acts as an 
osmotic buffer to reduce the osmotic shock that might otherwise result from the dilution of 
the cryoprotectant after cryostorage. In addition, permeating agents are able to compound 
with intracellular water and therefore water is very slowly removed from the cell. Hence the 
critical intracellular salt concentration is reached at a lower temperature. Removal of the 
cryoprotectant agent during warming can present a very real problem in terms of trying to 
reduce toxicity to the cells. Firstly, because of the toxicity of the vitrification solutions, quick 
dilution of them after warming is necessary; and secondly, during dilution water permeates 
more rapidly in to the cell than the cryoprotective additive diffuses out. As a consequence of 
the excess water inflow the cells are threatened by injury from osmotic swelling. In this 
situation the non-permeating sucrose acts as an osmotic buffer to reduce the osmotic shock. 
During warming using a high extracellular concentration of sucrose (e.g., 1.0M) 
counterbalances the high concentration of the cryoprotectant agents in the cell, as it reduces 
the difference in osmolarity between the intra- and extracellular compartments. The high 
sucrose concentration cannot totally prevent the cell from swelling, but it can reduce the 
speed and magnitude of swelling (Liebermann and Tucker, 2002; Liebermann et al., 2002a; 
2003). 
2. Oocytes 
The cryopreservation of human oocytes constitutes a important step forward in Assisted 
Reproductive Technology (ART) despite the fact that for more than 2 decades oocyte 
cryopreservation has long been the focus of unsuccessful efforts to perfect its clinical 
application. More recently, vitrification as an alternative to traditional slow freezing 
prootcols has been shown to provide high degrees of success in vitrified metaphase-II 
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human oocytes. Although oocyte cryopreservation historically has low efficiency mainly 
because of low rates of survival, fertilization, and cleavage, data on 2000 “frozen oocyte” 
babies born worldwide since 1986 exists. The question arises as to what makes oocytes so 
unique compared to embryos, besides differences in cell size and membrane permeability? 
Oocytes have a low volume-to-surface ratio; hence they are less efficient at taking up 
cryoprotectant and at loosing water. Other differences to be considered are a) that the 
maternal DNA is held suspended in the cytoplasm on the meiotic spindle & not within the 
protective confines of the nuclear membrane, therefore damage in the DNA and 
microtubules could explain the limited success of oocytes, b) the oocyte is arrested in a state 
primed for activation, and c) the changes in its environment can cause parthenogenetic 
activation. What are the applications then for oocyte cryopreservation in the US? One 
application would be to preserve fertility in women with malignant/premalignant 
conditions who would have to undergo treatment that might negatively impact their future 
ability to have children (50,000 per year <40 yr old), also in women who may want to delay 
childbearing (‘clock-tickers’) because of their careers, partnership status or psychological/ 
emotional reasons. A very interesting approach is donor oocyte banking, which makes the 
donor-recipient cycle more convenient by facilitating the “egg donation” and allows 
quarantining of the oocytes, which provides a unique advantage in economy as well as 
feasibility. Other applications are if a male is unable to produce a semen sample on the day 
of egg retrieval and or it could also eliminate ethical/moral questions of producing extra 
embryos. Overall, oocyte cryostorage offers an opportunity to reduce number of embryos 
generated per IVF cycle, and therefore lessening the pressure on the patient to increase the 
number of fresh embryos transferred. In addition, while also reducing embryo cryostorage it 
has the benefit of helping women “retain ownership” of their ability to be genetic parents at 
a time of their choosing, a time of greater convenience & health. The live born babies from 
cryopreserved oocytes have shown no apparent increase in congenital anomalies. Although 
13 years later after the first slow-freeze birth, the number of reported babies born as a result 
of vitrified oocytes is now approaching that of slow-frozen oocytes without any increasing 
risk in congenital abnormalities (Noyes et al., 2009). Vitrification of oocytes does not appear 
to increase risks of abnormal imprinting or disturbances in spindle formation or 
chromosome segregation (Trapphoff et al., 2010). It has the greatest potential for successful 
oocyte cryopreservation and with its increased clinical application is showing a trend to 
greater consistency and better outcomes (similar to outcomes between fresh or warmed 
oocytes). Vitrification of oocytes, when applied to properly screened patients, will be a 
useful technology in reproductive medicine practice and will constitute a major step 
forward in ART. 
Fortunately to date, no significant increase in abnormalities has been reported from these 
cryostored oocyte pregnancies (Chian et al., 2009), regardless of the historical concerns that 
cryopreservation of mature oocytes might disrupt the meiotic spindle and thus increase the 
potential for aneuploidy in the embryos arising from such eggs. These concerns have mostly 
been allayed by publications that show no abnormal or stray chromosomes from previously 
frozen oocytes (Gook & Edgar, 1999), and FISH comparison of embryos from fresh and 
thawed oocytes show no increase in anomalies (Cobo et al., 2001). There also appears to be 
adequate recovery of the meiotic spindle post-cryopreservation whether using conventional 
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or vitrification technology (Chen et al., 2004; Bianchi et al., 2005; Larman et al., 2007). The 
scientific literature on oocyte cryopreservation grows daily it seems. Most reports focus on 
clinical pregnancy rates (Boldt et al., 2003; Boldt et al., 2006), and as such while this data is 
helpful to increase our confidence in the technology, it does little to research new directions 
for oocyte cryopreservation.  
3. Zygotes 
Conventional cryopreservation of pronuclear zygotes (2PN) is well established in countries 
such as Germany where freezing of later stage human embryos is by law or by ethical 
reasons not allowed. The time to complete the conventional protocol to cryopreserved 
zygotes is 98min. In Germany the clinical pregnancy outcomes arising from the 
frozen/thawed 2PN cycles is about 18%, with an implantation of around 10% per embryo 
transferred. The time to complete vitrification of zygotes requires approximately 12min. 
Recently successful vitrification of 2PN with high survival (~ 90%), cleavage rates on day-2 
(>80%), and blastocyst formation of 31% and pregnancies were reported (Park et al., 2000; 
Jelinkova et al., 2002; Liebermann et al., 2002b; Al-Hasani et. al., 2007). Zygote vitrification 
implemented as a clinical setting can provide a clinical pregnancy rate of close to 30%, with 
an implantation rate of 17% (Al-Hasani et al., 2007). The pronuclear stage appears well-able 
to withstand the vitrification and warming conditions, which is probably due to the 
significant membrane permeability changes that occur post-fertilization; such changes to the 
oolemma may also make it more stable and able to cope with the vagaries of the cold-shock 
and striking osmotic fluctuations that occur during the vitrification process. 
4. Cleavage stage embryo 
Reports of human embryo vitrification have been more frequent. Liebermann and Tucker 
(2002) using either the cryoloop or the hemi-straw system (HSS) showed post-warming 
survival rates (after 2 hours of culture of day-3 embryos where more than half of their 
blastomeres were intact) from 84 to 90% which was dependent on the carrier system used. 
There was a reasonable further cleavage and compaction rate of 34%. This finding supports 
previous reports in which high survival rates of eight-cell human embryos using 40% EG 
were documented (Mukaida et al., 1998). In comparison to traditional slow-rate 
cryopreservation, a survival rate of cleavage stage embryos of 76% was reported with 
vitrification (Jericho et al., 2003). Recently reported successful pregnancies and deliveries 
after vitrification of day-3 human embryos using the OPS have been reported (El-Danasouri 
and Selman, 2001; Selman and El-Danasouri, 2002). Their results showed a negative 
correlation between stage of development and survival, eight-cell embryos showed a higher 
survival rate (79.2%; 62/78) than did embryos with fewer than six cells (21.1%; 11/53) after 
vitrification (El-Danasouri and Selman, 2001). Despite the fact, that Liebermann and Tucker 
(2002) achieved a promising post-warming survival rate, overall only about 34% of the 
surviving embryos had the developmental potential to reach the compaction stage. Recently 
publications on cleavage stage vitrification provided good outcome data. Loutradi et al. 
(2008) were performing a meta-analysis and systematic review by comparing traditional and 
vitrification protocols for cleavage stage embryos, and found a survival rate of 84.0% versus 
97.0%. In addition, clinical pregnancy rates between 35 and 48%, with implantation rates 
between 15 to 39% have been reported (Rama Raju et al., 2005; Desai et al., 2007; Li et al., 
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2007; Balaban et al., 2008). So clearly vitrification appears to have a positive impact on 
overall embryo utilization. A study on the neonatal outcome of 907 vitrified/warmed 
cleavage stage embryos found no significant increase in the congenital birth defect rate 
when compared with pregnancies using fresh cleavage stage embryos (Rama Raju et al., 
2009). 
5. Blastocyst stage 
Vitrification of human blastocysts using different carriers shows survival rates of 70% to 
90%, with clinical pregnancy rates of 37% to 53% and implantation rates of 20% to 30% 
((Yokota et al., 2000, 2001; Reed et al., 2002; Mukaida et al., 2001; 2003; Hiraoka et al., 2004; 
Vanderzwalmen et al., 2002; 2003; Huang et al., 2005; Liebermann & Tucker, 2006; 
Liebermann, 2009, 2011). 
6. The advantage of blastocyst cryopreservation 
Activation of the embryonic genome occurs after the 8-cell stage (3 days postoocyte retrieval) 
is reached (Braude et al., 1988). If the activation does not occur, the embryo will not survive 
further. Therefore, the improvement of human IVF outcomes requires identification of 
embryos that will progress beyond the 8-cell stage. Blastocyst culture (5 days postoocyte 
retrieval) allows for the transfer of embryos that clearly have an activated embryonic genome. 
This requires that the elimination of embryos in extended culture from day 3 to day 5 should 
depend solely on their inherited survival potential and not be a consequence of an adverse 
effect exerted by the sequential media used for culture beyond day 3. Additional advantages in 
cryopreserving at the blastocyst stage are: 1) At this stage a lower numbers of embryos can be 
transferred in fresh cycles, resulting in less high order multiple pregnancies, 2) The same is 
true for cryopreserved blastocysts showing higher pregnancy rates and implantation per 
thawed embryo transferred, 3) Approximately 120 hours (day five) into development the 
healthy human embryo should be at the blastocyst stage comprised of some 50 to 150 cells, of 
which about 20 to 30% make up the inner cell mass (ICM), the remainder making up the 
trophectoderm (TE), 4) the higher cell number allows better compensation for cryo-injuries, 
which results in greater viability and faster recovery, 5) the cytoplasmatic volume of the cells is 
lower, thus the surface-volume ratio is higher, and that in turn  makes the penetration of the 
cryoprotectant faster, and 6) on average fewer embryos per patient were frozen-stored, but 
each one when thawed has  a greater potential for implantation. 
Both natural and hormone replacement cycles seem to provide comparable levels of 
receptivity in naturally cycling women, though they differ in level of convenience. Regardless 
of the day of cryopreservation of the embryo (whether day 5, 6 or 7), at thawing/warming 
blastocysts should be treated as if they had been frozen on the fifth day of development. 
Vitrification of blastocysts has been undertaken utilizing an “open system” (Cryotop; Kitazato 
Bio Pharma Co. Ltd., Fuji-shi, Japan), and since 2007 on a “closed system” (HSV [High Security 
Vitrification Kit]; CryoBio System, L’Aigle, France) after a two-step loading with 
cryoprotectant agents at 24°C. Briefly, blastocysts were placed in equilibration solution, which 
is the base medium (Hepes-buffered HTF with 20% Serum Supplement Substition (SSS) 
containing 7.5% (v/v) ethylene glycol (EG) and 7.5% (v/v) dimethyl sulfoxide (DMSO). After 
5-7 min, the blastocysts were washed quickly in vitrification solution, which is the base 
medium containing 15% (v/v) DMSO, 15% (v/v) EG, and 0.5M sucrose, for 45-60sec and 
transferred onto the Cryotop or HSV using a micropipette. Immediately after the loading of 
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not more than two blastocysts in a 1l drop on the Cryotop, the carrier was plunged into fresh 
clean liquid nitrogen (LN2). After loading the embryos, the Cryotop was capped under the 
LN2 to seal and protect the vitrified material prior to cryo storage. In contrast, after loading the 
HSV, the straw was heat sealed and then plunged in LN2, and stored the same way as the 
cryotop (Liebermann & Tucker, 2006; Liebermann, 2009, 2011). 
To remove the cryoprotectants, blastocysts were warmed and diluted in a two step process. 
With the Cryotop or HSV submerged in LN2, the protective cap (Cryotop) or inner straw 
(HSV) were  removed, and then both carriers with the blastocysts were removed from the LN2 
and placed directly into a pre-warmed (~35-37oC) organ culture dish containing 1ml of 1.0M 
sucrose. Blastocysts were picked up directly from the Cryotop and placed in a fresh drop of 
1.0M sucrose at 24°C. After 5min blastocysts were transferred to 0.5M sucrose solution. After 
an additional 5min, blastocysts were washed in the base medium and returned to the culture 
medium (SAGE Blastocyst Medium, Trumbull, CT, USA) until transfer. 
Between January 2004 and July 2011 the Fertility Centers of Illinois “IVF Laboratory River 
North“(Chicago) has vitrified 13,568 blastocysts without artificial shrinkage before the 
cryopreservation procedure (Table 1). After 2562 frozen embryo transfers (FET) including 
day 5 and day 6 blastocysts with a mean age of the patients of 34.9 ± 5.1 years, to date we 
have seen a survival rate, implantation, and clinical pregnancy rate per transfer (cPR) of 
97.3%, 30.2%, and 42.5%, respectively (Table 2). After 7 1/2years of vitrifying blastocysts the 
perinatal outcome is as follow: from 687 deliveries with vitrified blastocysts, 852 babies (422 
boys and 430 girls) were born (Table 2). No abnormalities were recorded. The singleton, 
twin and triplet pregnancy rates were 71%, 27%, and 2%, respectively. 
Day of Development Day 5 Day 6 Day 7 Total 
Number of Blastocysts vitrified (%) 
6220
(46%)
6988
(51%)
360
(3%)
13568 
Table 1. Retrospective data from 3,712 patients (average age 33.8±4.9) with blastocyst 
cryopreservation by vitrification from January 2004 till July 2011. 
Technique VIT
Patient’s age (y) 34.9  5.1
No. of warmed cycles 2580
No. of transfers 2562
No. of blastocysts warmed 4965
No. of blastocysts survived (%) 4829 (97.3)
No. of blastocysts transferred 4752
Mean no. of blastocysts transferred 1.8
No. of implantations (%) 1432 (30.2)
No. of positive pregnancy/warm (%) 1255 (48.6)
No. of positive pregnancy/VET (%) 1255 (49.0)
No. of clinical pregnancy/warm (%) 1089 (42.2)
No. of clinical pregnancy/VET (%) 1089 (42.5)
Ongoing pregnancies/VET (%) 875 (34.2)
No. of livebirths 852 (422 boys & 430 girls) 
Table 2. Retrospective data from the blastocyst cryopreservation program (Fertility Centers 
of Illinois, Chicago) where vitrification (VIT) technology was applied from January 2004 till 
July 2011. 
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When the vitrified-warmed blastocysts were divided into day 5 and day 6 groups, the 
following data was gather (Table 3 & 4). In 1265 FETs transferring day 5 blastocysts, the 
survival, implantation, and cPR were 97.6%, 34.8%, and 48.3% compared to 97.2%, 25.3%, 
and 36.5% of in 1204 day 6 FETs.  
 
Patient's Age < 35 35-37 38-40 > 40 Donor Total 
Ø Age 30.8±2.6 35.8±0.8 38.8±0.8 42.8±2.0 43.5±4.7 34.6±5.2 
Day 5 Cycles 678 248 157 74 112 1269 
Day 5 Transfers 677 247 155 74 112 1265 
Embryos survived (%) 97.5% 96.9% 98.7% 96.0% 97.7% 97.6 
Embryos transferred (MEAN) 1.9 1.8 1.9 1.9 1.8 1.9 
Positive Pregnancies/Transfer 56.1% 56.7% 56.1% 51.4% 54.5% 55.8% 
Clinical Pregnancies/Transfer 50% 49% 43% 43% 50% 48.3% 
Ongoing Pregnancies/Transfer 43% 37% 30% 30% 39% 38.8% 
# Sacs 478 152 87 42 69 828 
Implantation Rate 37.3% 33.3% 29.7% 29.2% 33.7% 34.8% 
 
Table 3. Retrospective outcome data at FCI from vitrified day 5 blastocysts in regards to the 
patients age between June 2007 till July 2011. 
 
Patient's Age < 35 35-37 38-40 > 40 Donor Total 
Ø Age 31.0±2.4 36.0±0.8 38.8±0.8 42.5±1.8 43.9±4.9 35.1±5.0 
Day 5 Cycles 586 271 177 103 83 1220 
Day 5 Transfers 579 266 176 101 82 1204 
Embryos survived (%) 96.7% 97.8% 97.9% 95.2% 99.4% 97.2% 
Embryos transferred (MEAN) 1.8 1.8 1.8 1.7 1.8 1.8 
Positive Pregnancies/Transfer 43.0% 43.6% 39.2% 31.1% 50.0% 42.1% 
Clinical Pregnancies/Transfer 37% 38% 35% 29% 42% 36.5% 
Ongoing Pregnancies/Transfer 31% 30% 27% 20% 32% 29.2% 
# Sacs 276 128 80 34 41 559 
Implantation Rate 25.5% 26.5% 24.8% 19.0% 28.1% 25.3% 
 
Table 4. Retrospective outcome data at FCI from vitrified day 6 blastocysts blastocyst in 
regards to the patients age between June 2007 till July 2011. 
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In addition, in 1128 FET using aseptic vitrification, 2041 blastocysts were transferred with a 
survival, implantation, and cPR of 98.4%, 31.8%, and 44.2%, respectively (Table 5). After 4 
1/2 years of vitrifying blastocysts using a closed system the perinatal outcome is as follow: 
313 babies (165 boys and 148 girls) were born (Table 5). No abnormalities were recorded. 
 
 
 
Technique aVIT 
Patient’s age (y) 34.5  5.0 
No. of warmed cycles 1132 
No. of transfers 1128 
No. of blastocysts warmed 2102 
No. of blastocysts survived (%) 2069 (98.4) 
No. of blastocysts transferred 2041 
Mean no. of blastocysts transferred 1.8 
No. of implantations (%) 650 (31.8) 
No. of positive pregnancy/warm (%) 572 (50.7) 
No. of positive pregnancy/VET (%) 572 (53.9) 
No. of clinical pregnancy/warm (%) 499 (44.1) 
No. of clinical pregnancy/VET (%) 499 (44.2) 
Ongoing pregnancies/VET (%) 423 (37.5) 
No. of livebirths 313 (165 boys & 148 girls) 
 
 
 
Table 5. Retrospective data from the blastocyst cryopreservation program (Fertility Centers of 
Illinois, Chicago) where aseptic vitrification (aVIT) technology was applied from June 2007 till 
July 2011. 
Our data has shown that freezing at the blastocyst stage provides excellent survival, 
implantation and clinical pregnancy (Liebermann & Tucker, 2006; Liebermann, 2009, 
2011). To achieve this data the following points should be considered: a) without a 
successful blastocyst vitrification storage program, extended culture should never be 
attempted, b) the blastocyst is composed of more cells and therefore better able to 
compensate for cryo-injury, c) the cells are smaller thus making cryoprotectant 
penetration faster, and d) on average fewer embryos per patient are cryo-stored, but each 
one when thawed, has a greater potential for implantation, often with an opportunity for 
an ET with a single blastocyst. 
www.intechopen.com
 
Vitrification of Oocytes and Embryos 179 
Furthermore, a vitrification solution with a mixture of 7.5% EG/DMSO, followed by a 15% 
EG/DMSO with 0.5M sucrose step is safe for clinical use, giving rise to healthy babies 
without abnormalities. Vitrification of blastocysts using and open or closed system (Cryotop 
or HSV) is effective for achieving high implantation and pregnancy rates as seen in fresh 
embryo transfers. Although the outcome in terms of implantation and clinical pregnancy is 
significantly different when comparing day 5 blastocyst to day 6 blastocysts, our data 
should encourage cryopreservation of day 6 blastocysts as well. Based on the data 
presented, it is clear that the vitrification of Day 6 blastocysts is of clinical value since it can 
result in live births. This observation is confirmed by Saphiro et al. (2001) and Levens et al. 
(2008); they found that blastocyst development rate impacts outcome in slow cryopreserved 
blastocyst transfer cycles.  
In conclusion, vitrification of human blastocysts is a viable and feasible alternative to 
traditional slow freezing methods. The key to this success lies in the more optimal timing of 
embryo cryopreservation, e.g. individual blastocysts may be cryopreserved at their optimal 
stage of development and expansion. In addition, the repeatedly discussed topic of using 
open systems (direct contact between cells and LN2) and the possible danger of 
contamination by bacteria, fungus or different strains of virus from LN2, can be avoided by 
moving forward to a closed system providing lower cooling rates, but without a negative 
impact on the outcome. 
7. Contamination of LN2: Open versus closed systems 
There are many potential advantages of vitrification in that it is an easy, cheap, fast and 
an apparently successful cryopreservation method; however, there is one issue that is still 
up for debate. It has been shown that fungi, bacteria and viruses are able to survive in 
liquid nitrogen (LN2) (Tedder et al, 1995; Fountain et al, 1997; Bielanski et al, 2000; 2003; 
Kyuwa et al, 2003; Letur-Konirsch et al, 2003). Given the direct exposure of the human 
cells as they are directly plunged into LN2 during the vitrification process, this therefore 
raises the question as to whether the LN2 has to be sterilized, as it may be a possible 
source of contamination for those cells. To this point there has been no fungal, viral or 
bacterial contamination that has been described from about 400 publications related to 
vitrification since the first report in 1985. Bielanski and colleagues (2000) demonstrated a 
viral transmission rate of 21 % to human embryos stored in open freezing containers 
under experimental conditions of extremely elevated viral presence; while in contrast all 
embryos stored in sealed freezing containers were free from contamination. Based on this 
observation they proposed that the sealing of freezing containers appears to prevent 
exposure to potential contaminants. Commercial systems to purify LN2 by filtration have 
been developed, however this technology to date has received little practical application 
in IVF laboratories that have active cryopreservation programs. While it is not totally clear 
that contamination is a real risk in everyday use of LN2, nevertheless it may be prudent to 
consider routine sterilization of LN2 when open carrier systems are used for vitrification, 
followed by a sealing of that system for cryo-storage. Further there are currently at least 
three ‘closed’ sealed vitrification systems that are commercially available, with FDA 
clearance, that represent successful alternatives to open systems for embryo vitrification 
(Liebermann, 2009, 2011) 
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8. Conclusions and future directions 
Vitrification is a very promising cryopreservation method with many advantages, and an 
ever increasing clinical track record. A standardized vitrification protocol applicable to all 
stages of the pre-implantation embryo may not be realistic because of: a) different surface-
to-volume ratios; b) differing cooling rate requirements between oocytes, zygotes, cleavage 
stage embryos and blastocysts; and c) variable chill-sensitivity between these different 
developmental stages. Currently however, the most widely used protocol applied to any 
embryo stage is the two-step equilibration in an equi-molar combination of the 
cryoprotectants ethylene glycol and DMSO, at a concentration of 15% each (v/v) 
supplemented with 0.5 mol/l sucrose. 
For the adoption of vitrification in ART, as with all new technologies, there has been initial 
resistance; but as clinical data has been accrued, this technology is becoming more 
commonly adopted as standard procedure in many IVF programs worldwide. With this 
increased use in human assisted reproduction will come evolution of the vitrification 
process as it is fine tuned to clinical needs, so pushing forward its development to higher 
levels of clinical efficiency, utilization and universal acceptance. 
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